BiotechTube

Camrelizumab + Nab-Paclitaxel + Carboplatin

Phase 2/3UNKNOWN
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer

Trial Timeline

Jun 15, 2021 → Jun 30, 2025

NCT ID
NCT04907344

About Camrelizumab + Nab-Paclitaxel + Carboplatin

Camrelizumab + Nab-Paclitaxel + Carboplatin is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Triple Negative Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04907344. Target conditions include Triple Negative Breast Cancer.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT04907344Phase 2/3UNKNOWN

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
eFT508eFFECTOR TherapeuticsPhase 2
44
No drugDaiichi SankyoPre-clinical
23
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Abemaciclib + BicalutamideEli LillyPhase 2
52
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
77
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
33
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
77
Combination of Veliparib + LapatinibAbbViePre-clinical
23
Capivasertib + ItraconazoleAstraZenecaPhase 1
33
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
52
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
41
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
33
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
77
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
52
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
41

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85